Clinical trials: Pembrolizumab
Hodgkin Lymphoma
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth).
- Trial name
- NCT05508867
- Testing
- favezelimab/pembrolizumab, bendamustine, gemcitabine
- Where
- 105 sites in United States, Argentina and 18 more
- Volunteers
- 203 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer, Cancer
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers.
- Trial name
- NCT04274907
- Testing
- Venetoclax, Pembrolizumab
- Where
- 39 sites in United States
- Volunteers
- 2 people
- Sponsor
- AbbVie
Colorectal Cancer Metastatic, High Immune Infiltrate
Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate
About 85% of cases of non-metastatic colorectal cancer (CRC) are related to chromosomal instability and have a proficient DNA Mismatch-Repair system (pMMR); which are also called CRC with microsatellite stability (MSS).
- Conditions
- Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable
- Trial name
- POCHI (NCT04262687)
- Testing
- Capecitabine, Oxaliplatin, Bevacizumab
- Where
- 88 sites in France
- Volunteers
- 55 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC
This study is the study of the combination of PEGPH20 and Pembrolizumab (MK-3475) for patients with previously treated Hyaluronan High (HA-high) metastatic pancreatic ductal adenocarcinoma.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreatic Neoplasms
- Trial name
- NCT03634332
- Testing
- PEGPH20, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pancreatic Cancer Research Team
Non-Small Cell Lung Cancer, Melanoma
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in participants with NSCLC.
- Conditions
- Non-Small Cell Lung Cancer, Melanoma, Mismatch Repair-Proficient Colorectal Cancer
- Trial name
- NCT02437136
- Testing
- entinostat, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 191 people
- Sponsor
- Syndax Pharmaceuticals
Urothelial Carcinoma, Triple Negative Breast Cancer
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
This is a first-in-human, open-label, multicenter, dose-escalation and expansion study designed to investigate SBT6290 administered alone and in combination with pembrolizumab in advanced solid tumors associated with Nectin-4…
- Conditions
- Urothelial Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT05234606
- Testing
- SBT6290, pembrolizumab
- Sponsor
- Silverback Therapeutics
Multiple Myeloma
Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)
This is a phase I/II, single arm, open label, two-part study that will assess safety, tolerability and clinical activity of GSK2857916 given in combination with a programmed cell death-1 (PD-1) inhibitor pembrolizumab in subjects…
- Trial name
- DREAMM 4 (NCT03848845)
- Testing
- belantamab mafodotin, Pembrolizumab
- Where
- 12 sites in United States, Canada and 2 more
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Carcinoma of Unknown Primary
Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)
Abbreviated Title: Pembrolizumab in Patients with Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) Trial Phase: 2 Clinical Indication: Treatment naïve patients with poor prognosis carcinoma of unknown primary site Trial…
- Trial name
- CUP (NCT03391973)
- Testing
- Pembrolizumab Injection
- Where
- 3 sites in Canada
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- AHS Cancer Control Alberta
Stage IIIA Uveal Melanoma, Stage IIIB Uveal Melanoma
Pembrolizumab in Treating Patients With Advanced Uveal Melanoma
This phase II trial studies how well pembrolizumab works in treating patients with uveal melanoma that has spread to other places in the body and usually cannot be cured or controlled with treatment.
- Conditions
- Stage IIIA Uveal Melanoma, Stage IIIB Uveal Melanoma, Stage IIIC Uveal Melanoma, Stage IV Uveal Melanoma
- Trial name
- NCT02359851
- Testing
- Pembrolizumab, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Gastric Cancer, GastroEsophageal Cancer
Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
This study is an open-label, phase II study with a safety lead-in to assess the response rate of induction olaparib and stereotactic beam radiotherapy (SBRT) followed by combination olaparib/pembrolizumab in patients with…
- Trial name
- NCT05379972
- Testing
- Pembrolizumab, Olaparib, Stereotactic Body Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of Colorado, Denver
Metastatic Solid Tumor, Advanced Solid Tumor
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.
- Trial name
- NCT05479812
- Testing
- WTX-124, pembrolizumab
- Where
- 14 sites in United States
- Volunteers
- 156 people
- Sponsor
- Werewolf Therapeutics, Inc.
Advanced Solid Tumors
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Immune therapies work with the body's immune system to treat a number of cancers. They work with T-cells, a type of white blood cell, to target and attack specific tumors.
- Trial name
- NCT05083481
- Testing
- ASP1570, pembrolizumab, Trifluridine + Tipiracil
- Where
- 30 sites in United States, China and 4 more
- Volunteers
- 226 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Melanoma (Skin), Non-Small-Cell Lung Carcinoma
Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma
From Protocol v3.0 dated 16Jun2022. This is an international, multicenter, open-label, multiple cohort, First in Human, phase 1b clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any…
- Trial name
- NCT04990479
- Testing
- GAd-PEV, MVA-PEV
- Where
- 7 sites in Belgium, Spain and 1 more
- Volunteers
- 7 people
- Sponsor
- Nouscom SRL
Non-squamous Non-small-cell Lung Cancer, EGFR Activating Mutation
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations
The purpose of this study is to assess the safety and efficacy of pemetrexed + carboplatin + pembrolizumab (MK-3475) with lenvatinib (MK-7902/E7080) in patients with advanced nonsquamous non-small cell lung cancer harboring EGFR…
- Trial name
- NCT05258279
- Testing
- Pembrolizumab, Lenvatinib, Carboplatin
- Where
- 10 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Juntendo University
GBM
Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma
This will be a prospective, open label, single center, phase I lead-in study of 10 patients to a single arm phase-II study of 37 additional patients to assess the effectiveness of pembrolizumab and lenvatinib combination therapy…
- Trial name
- NCT05973903
- Testing
- Lenvatinib, Pembrolizumab, Tumor Treating Fields (TTFields)
- Sponsor
- Tel Aviv Medical Center
Non-small Cell Lung Cancer
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
This is a phase 3, randomized, double-blind study of adjuvant calderasib plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) versus adjuvant placebo plus MK-3475a in participants with completely resected stage…
- Trial name
- KANDLELIT-013 (NCT07431827)
- Testing
- Calderasib, MK-3475A
- Where
- 120 sites in Argentina, Australia and 17 more
- Volunteers
- 400 people
- Sponsor
- Merck Sharp & Dohme LLC
Biliary Tract Cancer, HER2 Gene Mutation
Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer
This is a multicenter, single arm, prospective, open-label phase II trial investigating the clinical activity triplet regimen consisting of a combination of chemotherapy (gemcitabine/cisplatin) + trastuzumab + pembrolizumab as…
- Conditions
- Biliary Tract Cancer, HER2 Gene Mutation, HER2
- Trial name
- TRAP-BTC (NCT06178445)
- Testing
- SOC plus trastuzumab and pembrolizumab
- Where
- 8 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Metastatic Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
PSMA Therapy and Immunotherapy in Kidney Cancer
This is a multi-center, single arm open label phase 1b/2 study of pembrolizumab in combination with 177Lu-PNT2002 (also known as 177Lu-PSMA I\&T) radiopharmaceutical therapy in patients with metastatic clear cell renal cell…
- Trial name
- NCT06361810
- Testing
- Pembrolizumab, 177Lu-PNT2002, (F-18)-DCFPyL
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoma
Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas
To determine the safety and efficacy (overall response rate) of pembrolizumab in patients with relapsed or refractory ENKTL, and EBV-DLBCL
- Trial name
- NCT03586024
- Testing
- Pembrolizumab
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Lymphoma, B-Cell
A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)
The purpose of this study is to evaluate the objective response, safety, and tolerability of pembrolizumab in Japanese participants who have refractory primary mediastinal large B-cell lymphoma.
- Trial name
- NCT04317066
- Testing
- Pembrolizumab
- Where
- 9 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.